Ocrelizumab (Ocrevus) (Hoffmann-La roche limited) (May 2018)
The current CADTH Common Drug Review (CDR) submission for ocrelizumab is for use in the treatment of patients with primary progressive MS (PPMS). CADTH has previously reviewed ocrelizumab for use in the treatment of adult patients with relapsing remitting MS (RRMS).
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa (ON) :
CADTH
2018.
|
| Colección: | Common drug review clinical review report
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820425506719 |
| Sumario: | The current CADTH Common Drug Review (CDR) submission for ocrelizumab is for use in the treatment of patients with primary progressive MS (PPMS). CADTH has previously reviewed ocrelizumab for use in the treatment of adult patients with relapsing remitting MS (RRMS). |
|---|---|
| Descripción Física: | 1 online resource (89 pages) : illustrations |
